Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celgene has said its cancer drug Revlimid has demonstrated positive results against an incurable blood cancer known as myelodysplastic syndromes in a phase III trial.
Subscribe to our email newsletter
This breakthrough data showed that in myelodysplastic syndrome (MDS) patients with chromosome 5q deletion treatment, Revlimid can provide long-term durable results and help them to remain transfusion free.
MDS is a cancer in which the bone marrow fails to make enough functioning blood cells and patients need whole-body blood transfusions as much as twice a month. Repeated transfusions can lead to a toxic buildup called “iron overload” that severely damages the heart, liver and pancreas, and patients eventually succumb to the disease.
The data presented showed that two-thirds of patients who received Revlimid were completely freed from the need for blood transfusions. More significantly, in 44% of patients, there was no detectable trace of the cancer.
Additional research has evaluated Revlimid in MDS not associated with a chromosome 5q abnormality. In this phase II trial, nearly one-third of Revlimid patients remained blood transfusion free for a median duration of 41 weeks.
These data results demonstrate that Revlimid can provide long-term clinical benefit in MDS patients with or without the chromosome 5q abnormality and dramatically help improve their quality of life.